WEREWOLF THERAPEUTICS, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
WEREWOLF THERAPEUTICS, INC. (HOWL) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 8.21 million shares for the 6-month period ending 2026-06-30, per its S-4 filed 2026-09-22.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-09-22
- WEREWOLF THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 8.46M shares, a 18.85% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 10.42M shares, a 31.82% increase year-over-year.
- WEREWOLF THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 7.91M shares, a 11.08% increase year-over-year.
- WEREWOLF THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 7.12M shares, a 60.80% increase year-over-year.
- WEREWOLF THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 6.14M shares, a 7.09% increase from fiscal 2022.
- WEREWOLF THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 5.74M shares, a 58.46% increase from fiscal 2021.
- WEREWOLF THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2021 was 3.62M shares, a 82.73% decline from fiscal 2020.
- WEREWOLF THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2020 was 20.96M shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 8.21M shares S-4 · filed 2026-09-22 | |||||||
| 2026-03-31 | 8.46M shares 10-Q · filed 2026-05-07 | |||||||
| 2025-12-31 | 10.04M shares S-4 · filed 2026-09-22 | |||||||
| 2025-09-30 | 10.25M shares 10-Q · filed 2025-11-04 | |||||||
| 2025-06-30 | 11.32M shares S-4 · filed 2026-09-22 | 10.53M shares 10-Q · filed 2025-08-14 | ||||||
| 2025-03-31 | 10.42M shares 10-Q · filed 2026-05-07 | 11.21M shares 10-Q · filed 2025-05-08 | ||||||
| 2024-12-31 | 7.76M shares S-4 · filed 2026-09-22 | |||||||
| 2024-09-30 | 7.75M shares 10-Q · filed 2025-11-04 | |||||||
| 2024-06-30 | 7.76M shares 10-Q · filed 2025-08-14 | |||||||
| 2024-03-31 | 7.91M shares 10-Q · filed 2025-05-08 | |||||||
| 2023-12-31 | 6.14M shares 10-K · filed 2025-03-11 | |||||||
| 2023-09-30 | 6.88M shares 10-Q · filed 2024-11-07 | 6.86M shares 10-Q · filed 2023-11-14 | ||||||
| 2023-06-30 | 7.14M shares 10-Q · filed 2024-08-08 | 7.12M shares 10-Q · filed 2023-08-10 | ||||||
| 2023-03-31 | 7.12M shares 10-Q · filed 2024-05-03 | 7.08M shares 10-Q · filed 2023-05-11 | ||||||
| 2022-12-31 | 5.74M shares 10-K · filed 2024-03-07 | 5.71M shares 10-K · filed 2023-03-23 | ||||||
| 2022-09-30 | 5.70M shares 10-Q · filed 2023-11-14 | |||||||
| 2022-06-30 | 4.86M shares 10-Q · filed 2023-08-10 | |||||||
| 2022-03-31 | 4.43M shares 10-Q · filed 2023-05-11 | |||||||
| 2021-12-31 | 3.62M shares 10-K · filed 2023-03-23 | |||||||
| 2021-09-30 | 3.38M shares 10-Q · filed 2022-11-10 | |||||||
| 2021-06-30 | 3.38M shares 10-Q · filed 2022-08-11 | |||||||
| 2021-03-31 | 21.24M shares 10-Q · filed 2022-05-10 | |||||||
| 2020-12-31 | 20.96M shares 10-K · filed 2022-03-24 | |||||||
| 2020-06-30 | 10.42M shares 10-Q · filed 2021-08-12 | |||||||
| 2020-03-31 | 6.75M shares 10-Q · filed 2021-06-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |